Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2026-08-31 21:59:36 ET · period of report 2026-08-28 · accession 0001193125-26-377309 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-08-31 21:59 | 2026-08-28 | XENE | KENNEY CHRISTOPHER JOHN | Chief Medical Off | S - Sale | $60.25 | -7,068 | 2 | -100% | -$425.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-08-28 | S | D | 6,368 | $60.17 | 702 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026. (F2) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $59.79 to $60.68, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 2 | Common | Common Shares | 2026-08-28 | S | D | 700 | $60.98 | 2 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026. (F3) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $60.81 to $61.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. (F4) The number of shares beneficially owned following the reported transactions reflects an upward adjustment of one share from the reporting person's previous Form 4 filed on March 13, 2026, based on updated tax withholding calculations for the transactions described on the previously filed Form 4. |